Latest Annual Report
Filed: 2026-02-17
Key Insights
- Cogent Biosciences, Inc. (COGT) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for cancer and other serious diseases. The company's lead product candidate, CGT9486, is in late-stage development for the treatment of advanced solid tumors.
- The company has a diverse pipeline of early-stage preclinical and discovery programs targeting various disease areas, which could provide potential upside in the future.
- Cogent Biosciences has secured a credit facility of up to $100 million to fund its ongoing operations and development activities, which should provide financial flexibility in the near term.